EPICENTRX, INC.
30Patents
30Active
30Granted
55Portfolio score
Filing activity: Sep 6, 2007 → Apr 29, 2024 · 1 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9139519B2 | Organonitro thioether compounds and medical uses thereof | Chemistry; Metallurgy | 16 | Active |
| US8927527B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | Chemistry; Metallurgy | 16 | Active |
| US9468625B2 | Organonitro thioether compounds and medical uses thereof | Chemistry; Metallurgy | 14 | Active |
| US9226915B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | Chemistry; Metallurgy | 14 | Active |
| US9987270B1 | Treatment of gliomas using organonitro compound combination therapy | Human Necessities | 13 | Active |
| US10342778B1 | Treatment of brain metastases using organonitro compound combination therapy | Human Necessities | 12 | Active |
| US10543208B2 | Treatment of gliomas using organonitro compound combination therapy | Human Necessities | 11 | Active |
| US10149832B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | Chemistry; Metallurgy | 11 | Active |
| US11008287B2 | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine | Emerging Cross-Sectional Technologies | 9 | Active |
| US11160784B1 | Treatment of brain metastases using organonitro compound combination therapy | Human Necessities | 8 | Active |
| US11510901B2 | Methods and compositions utilizing RRx-001 combination therapy for radioprotection | Human Necessities | 6 | Active |
| US11576895B2 | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone | Human Necessities | 4 | Active |
| US9511016B2 | Topical composition for treating pain | Human Necessities | 4 | Active |
| US11744859B2 | Compositions and methods for parenteral administration of therapeutic agents | Emerging Cross-Sectional Technologies | 2 | Active |
| US10906957B2 | Immunomodulatory fusion proteins | Chemistry; Metallurgy | 2 | Active |
| US11701351B2 | Treatment of gliomas using organonitro compound combination therapy | Human Necessities | 2 | Active |
| US11925617B2 | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US11660286B2 | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products | Emerging Cross-Sectional Technologies | 2 | Active |
| US12109348B2 | Medication infusion devices, systems, and methods | Human Necessities | 2 | Active |
| US12048793B2 | Medication infusion devices, systems, and methods | Human Necessities | 2 | Active |
| US11834492B2 | Human IL-10 receptor alpha fusion proteins | Chemistry; Metallurgy | 1 | Active |
| US11253608B2 | Recombinant adenoviruses carrying transgenes | Chemistry; Metallurgy | 1 | Active |
| US12291726B2 | A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter | Chemistry; Metallurgy | 0 | Active |
| US11999973B2 | Method for producing recombinant oncolytic adenovirus with modified E1a cancer-specific promoter | Chemistry; Metallurgy | 0 | Active |
| US12054530B2 | Immunomodulatory fusion proteins | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.